Lance . . . For your info UPCA was picked by the following newsletter today. I do not own it. It seems suspect to me. No info was given on what stage of controlled Clinical Trails they are in(Phase 1, 2, 3, etc.).
ProfitPickers - profitpicks.com
Dear ProfitPickers!
We would like to share with you a company which we see great risk, but
extraordinary potential in.
ProfitPick! UPCA
Recent Price: $1.75
Instead of giving a detailed research report of UPCA, we feel that all of you will see the potential in this great company simply by its latest press release from 7/19/99.
It reads:
"Monday July 19, 8:25 am Eastern Time
Company Press Release
New Technologies & Concepts, Inc. Receives Patient Documentation From
Govt. Of Spain Following Announcement Of Major Breakthrough In Field Of HIV Research
LAS VEGAS--(BW HealthWire)--July 19, 1999--New Technologies & Concepts, Inc. (NTC), a Research and Development Company, announced today that as a follow-up to its announcement on June 16, 1999 of its major breakthrough in the fight against the human immunodeficiency virus (HIV), it has received documentation from the Government of Spain verifying the authenticity of the patients who have been treated and sent letters regarding their treatment. Their regular monthly checkups have shown no recurrence of the virus to date. In fact, ONE HUNDRED PERCENT (100%) of the patients tested showed COMPLETE REVERSAL of the HIV virus with VIRTUALLY NO SIDE EFFECTS!
The founder of the company, Alfred Flores, an honor graduate of the
University of Madrid and the University of Colorado, has done extensive research into the area of immunology at his own laboratory located just outside of Lisbon, in Portugal. It was there that he developed the Plasma Plus formula, which was used to treat these patients. The letters received further verify that the tests conducted on patients in Madrid, which showed complete reversal from the immune system of the HIV infection, still show no reintroduction of the virus after a period of more than eighteen months.
The letters give the patient's name and address, their patient number,
identification number, their original CD-4 counts at the commencement of the treatment, and their current CD-4 counts after more than 18 months.
The patients were originally diagnosed with AIDS in 1995 at the Hospital of Madrid and Mr. Flores was then given permission by the courts to treat them with Plasma Plus which is done, in most cases, over a 3-month period.
This documentation verifies that all of the patients have been tested
monthly at the General Hospital in Madrid over the past 18 months. Their blood profiles show that prior to being administered the Plasma Plus treatment, some of the patients had CD-4 counts under 400, usually associated with AIDS, and some even as low as 200.
They are all currently in the normal 800 - 1,200 CD-4 count range and
aside from taking vitamins and following a low calorie diet, they have not taken any medication of any kind for the virus since the original Plasma Plus treatments.
Results from the findings of the Plasma Plus treatment are nothing short of ''Phenomenal,'' according to the doctors in Madrid who oversaw the treatments.
The majority stockholder in NTC is Uniprime Capital Acceptance, Inc. (OTC BB: UPCA - news) of Las Vegas, Nevada, a diversified holding company involved in the acquisition of retail automotive dealerships throughout the United States, along with planned expansion into the areas of non-prime financing, industry consulting and insurance-related services.
NTC and Uniprime are currently working on additional sites around the
world to demonstrate the results of Plasma Plus before embarking on a
worldwide marketing campaign.
The documentation regarding five (5) of the patients will be posted on the Uniprime web-site which is located at: www.uniprimeinc.com .
In addition to the testimonials of the patients, three (3) of the doctors who participated in the study will be forwarding their own WRITTEN TESTIMONIALS as to the results of the tests and this information is expected to be in the hands of Mr. Flores and top Uniprime personnel by next week.
For further information, please contact Mr. Alfred Flores through the
corporate offices of Uniprime at 1-888-892-2002 Or 1-702-798-5420.
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: The statements contained herein which are not historical are forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those expressed in the forward-looking statements, including, but not limited to, certain delays beyond the company's control with respect to market acceptance of new technologies or products or delays in testing and evaluation of products or in information supplied by others and other risks detailed from time to time in company documents furnished to investors."
At this point, we would like to bring something to your attention. Do any of you remember ENMD? It skyrocketed from 12 to 84 on an announcement not half as good as UPCA's press release. Yet, UPCA has only moved 22% on the news! We strongly expect growing popularity and the spread of this recent news release to cause a big jump in the stock price.
To conclude, maybe this "Plasma Plus" cure may turn out to be nothing. Or it may turn out to be the cure for AIDS. If this is true, what will UPCA be then? The potential is mind-blowing.
The risk is very, very high, but the potential is far, far beyond the
heights of the sky.
Feel free to discuss UPCA on our Rumor Board.
Regards,
ProfitPicks.com
profitpicks.com |
